Consolidated Profit after Taxes and Minority Interest (PAT) has been registered at Rs 7 crore
HealthCare Global Enterprises (HCG) announced its unaudited financial results for the third quarter and nine months ended December 31, 2024.
Highlights for quarter ended December 31, 2024
- Consolidated Income from Operations (Revenue) was Rs 558 crore as compared to Rs 469 crore in the corresponding quarter of the previous year, reflecting a year-on-year growth of 19 per cent
- Consolidated Profit Before Depreciation and Amortization, Finance Costs, Exceptional Items and Taxes (Adjusted EBITDA) was Rs 92 crore, as compared to Rs 80 crore in the corresponding quarter of the previous year, a growth of 15 per cent year-on-year.
- Consolidated Profit Before Other Income, Depreciation and Amortization, Finance Costs, Exceptional Items and Taxes (Reported EBITDA), was Rs 88.4 crore, as compared to Rs 78.6 crore in the corresponding quarter of the previous year, a growth of 12 per cent year-on-year.
- EBITDA for Established centres was Rs 105 crore, a growth of 14 per cent year-on-year
- EBITDA from Emerging centres was Rs 3 crore, as compared to Rs 2 crore in the corresponding quarter of the previous year
- Consolidated Profit after Taxes and Minority Interest (PAT) of Rs 7 crore, as compared to Rs 5 crore in the corresponding quarter of the previous year, growing by 23 per cent year-on-year
Dr BS Ajaikumar, Executive Chairman, HealthCare Global Enterprises said, "HCG has been at the forefront of cancer care, pioneering innovative approaches that integrate multi-disciplinary expertise, advanced molecular and genetic diagnostics, and a hub-and-spoke patient outreach model. These efforts enable us to deliver highly personalised care, and our strong performance stands as a testament to these strategies. Guided by our vision of making cancer care accessible and affordable, we are committed to reaching over 50 per cent of cancer patients in India through our unique hub-and-spoke model. In addition to our existing Centers of Excellence in Bengaluru, Mumbai, Ahmedabad and Kolkata, we are expanding our footprint by establishing multiple CoEs in Cuttack and Odisha."
Raj Gore, CEO, HealthCare Global Enterprises, added, “We are proud to announce highest ever quarterly revenues of Rs 558 crores with a robust growth of 19 per cent and EBITDA standing at Rs 87 crores with a growth of 11 per cent compared to the same period last year. Despite being a seasonally weaker quarter, we are proud to have achieved this performance based on improving volumes across modalities. The Oncology business post MG hospital acquisition grew by 24 per cent. Our emerging centres continue to perform well, the Kolkata centre grew by 40 per cent and the South Bombay centre grew by 28 per cent. South Bombay Centre witnessed strong performance despite challenges in international business, which we expect to recover by the upcoming quarter and will be key for the centre’s turnaround. We are confident of the robust growth in these centres with improving performance on the back of strong brand creation, quality clinical talent and increased awareness programs for cancer care and diagnosis.
